These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32495250)

  • 1. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
    Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E
    Rev Endocr Metab Disord; 2021 Sep; 22(3):581-594. PubMed ID: 32495250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Imaging in neuroendocrine neoplasias.
    Christ E; Wild D; Refardt J
    Presse Med; 2022 Jun; 51(2):104115. PubMed ID: 35131317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Imaging of Neuroendocrine Neoplasms.
    Refardt J; Hofland J; Wild D; Christ E
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2662-e2670. PubMed ID: 35380158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Directions in Imaging Neuroendocrine Neoplasms.
    Refardt J; Hofland J; Wild D; Christ E
    Curr Oncol Rep; 2021 Nov; 23(12):143. PubMed ID: 34735669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.
    Fani M; Peitl PK; Velikyan I
    Pharmaceuticals (Basel); 2017 Mar; 10(1):. PubMed ID: 28295000
    [No Abstract]   [Full Text] [Related]  

  • 6. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs.
    Reubi JC; Waser B
    J Nucl Med; 2015 Apr; 56(4):613-5. PubMed ID: 25698785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovative imaging of insulinoma: the end of sampling? A review.
    Christ E; Antwi K; Fani M; Wild D
    Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs).
    Effraimidis G; Knigge U; Rossing M; Oturai P; Rasmussen ÅK; Feldt-Rasmussen U
    Semin Cancer Biol; 2022 Feb; 79():141-162. PubMed ID: 33905872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
    Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
    J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
    Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
    Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
    Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiopeptide imaging and therapy in Europe.
    Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
    J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
    Reubi JC; Waser B
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):781-93. PubMed ID: 12707737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
    Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
    Körner M; Waser B; Reubi JC
    Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.
    Garcia-Carbonero R; JImenez-Fonseca P; Teulé A; Barriuso J; Sevilla I;
    Clin Transl Oncol; 2014 Dec; 16(12):1025-34. PubMed ID: 25183048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
    Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors.
    Vitali E; Piccini S; Trivellin G; Smiroldo V; Lavezzi E; Zerbi A; Pepe G; Lania AG
    Mol Cell Endocrinol; 2021 May; 527():111226. PubMed ID: 33675866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
    Regalla DKR; Deep O; Paluri RK
    Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.